Background: Immune checkpoint blockade (ICB) promotes adaptive immunity and tumor regression in some cancer patients. However, in patients with immunologically "cold" tumors, tumor-resident innate immune cell activation may be required to prime an adaptive immune response and so exploit the full potential of ICB. Whilst Toll-like receptor (TLR) agonists have been used topically to successfully treat some superficial skin tumors, systemic TLR agonists have not been well-tolerated.
Introduction
ICB monoclonal antibodies (mAbs) targeting inhibitory pathways at the T cell synapse to modulate T cell function have shown activity in the treatment of multiple cancers, as demonstrated by numerous regulatory approvals [1, 2] . However, monotherapy response rates to ICB mAbs remain low, and additional therapies are required. Clinical response to ICB mAbs correlates with the presence of high densities of tumor infiltrating CD8 + T cells (TILs, a so called "hot" tumor microenvironment) [3] . Patients with few TILs, so called "cold" tumors, tend to respond poorly to ICB mAbs. Therapeutic strategies that target tumor-resident innate immune cells and induce local tumor proinflammatory responses, which recruit CD8 + TILs, may be required to fully exploit the potential of ICB mAbs.
One strategy to turn an immunologically cold tumor hot is to promote activation of antigen presenting cells (APC) by targeting the endosomal TLRs TLR3, TLR7, TLR8, TLR9, or by targeting the ER-associated signalling molecule stimulator of interferon genes (STING). TLR3, TLR7, TLR8, and TLR9 recognise single and double stranded viral RNA and bacterial CpG DNA in the endosome following internalisation by APCs. STING senses aberrant DNA species or cyclic dinucleotides in the cytosol [4] . TLR and STING signalling activates APCs, increasing expression of inflammatory cytokines and co-stimulatory molecules, and enhancing antigen presentation capacity. Thus, APC activation by TLRs or STING can promote switching of CD4 + T cell response from Th2 to Th1, enhance CD8 + T cell responses, and inhibit T regulatory cell responses [5] [6] [7] [8] [9] . TLR7/8 agonists (imidazoquinolines), TLR9 agonists (synthetic CpG oligonucleotides) and STING agonists (cyclic di-nucleotides) have all shown potent antitumor activity in a range of murine cancer models [4] . The clinical utility of systemically delivered TLR agonists has been limited due to toxicity [10, 11] . In contrast, direct dermal application of Imiquimod (TLR7 agonist) or Resiquimod (TLR7/8 agonist) promotes local immune activation while limiting systemic exposure and side-effects and has clinical activity in treating multiple cutaneous tumor types [12] . Imiquimod is also approved as a topical treatment for external genital warts, actinic keratosis, and superficial basal cell carcinoma (Aldara approved product labelling; [12] [13] [14] [15] [16] ). However, the utility of these topical treatments is confined to patients with cutaneous lesions.
Intratumoral (IT) TLR or STING agonist therapy has the potential to treat patients with solid tumors. The potential of IT therapeutic anti-cancer agents in the clinic is underscored by the recent approval of the oncolytic viral product T-VEC [17, 18] . In preclinical models, TLR and STING agonists delivered IT have promising antitumor activity [4, 19] .
A TLR7/8 agonist has the potential to activate a broader range of human APCs versus targeting TLR9 within the tumor microenvironment, since TLR7 and TLR9 are both expressed on plasmacytoid dendritic cells (pDCs) and B cells, whereas TLR8 is more widely expressed on monocytes and myeloid dendritic cells (mDCs) [20] . Furthermore, it was hypothesized that retention of the TLR7/8 agonist in the tumor may be important for efficacy. Since the TLR7/8 agonist Resiquimod is known to distribute quickly into the systemic circulation after injection [21] , MEDI9197, a dual TLR 7/8 agonist, was designed with a lipid tail to reduce aqueous solubility leading to retention at the injection site, rather than rapidly distributing throughout the body. MEDI9197 has been shown to have activity in mouse vaccine and cancer models and synergize with other immunotherapies [22] [23] [24] .
In this manuscript we demonstrate that targeting TLR7 and 8 compared with TLR9 or STING in human PBMCs leads to induction of a broader range of cytokines. In murine syngeneic tumor models, MEDI9197 modulates the tumor microenvironment (TME) to an inflamed immunophenotype and increases the anti-tumor efficacy of immune co-stimulatory molecule agonists.
Materials and methods

TLR reporter assay
Human TLR7, human TLR8, or mouse TLR7 HEK293 reporter cells (InvivoGen) were seeded at 3 × 10 4 cells/ 96-well for 24 h then treated with MEDI9197 or DMSO for 24 h. Secreted alkaline phosphatase (SEAP) was measured from supernatants using QuantiBlue reagent (InvivoGen).
DC activation and cytokine production pDC and mDC were enriched from PBMCs by magnetic bead negative selection (Miltenyi Biotec). Cells were resuspended at 4 × 10 5 cells/mL in serum-free AIM V medium and cultured for 24 h in 96-well plates with MEDI9197 or DMSO. Supernatants were analysed for IFNα and IL-12p40 by ELISA (Mabtech and Affymetrix eBioscience, respectively).
IL-12 release in human macrophages
CD14
+ cells were purified from PBMCs using the EasySep™ Human Monocyte Enrichment Kit (StemCell Technologies) and differentiated into macrophages with 100 ng/mL recombinant human M-CSF (Peprotech). After 6 days cells were harvested, seeded in 96 well plates and rested overnight. Cells were primed with 20 ng/mL human recombinant IFNγ (R&D systems) for 24 h, followed by 3 μM MEDI9197 or 20 ng/mL LPS (Invivogen) for 24 h. Supernatants were analysed for IL-12p70 using the human IL12p70 ELISA Duoset kit (R&D). 
PBMC activation, cytokine and FACS analysis
PHA-induced cytokine assay
× 10
5 human PBMCs were seeded in 96-well plates and treated with MEDI9197 or DMSO for 2.5 h, then incubated with 10 μg/mL PHA-L (Roche) for 45.5 h at 37°C. IL-5 was assessed in supernatants using human IL-5 ELISA Set (BD OptEIA,) with DELFIA readout (Perkin Elmer).
Natural killer (NK) cell killing assay 2 × 10 6 cells/mL human PBMCs were cultured for 24 h at 37°C with 3 μM MEDI9197 or DMSO. NK cells were then isolated using an EasySep® Human NK Cell Enrichment Kit (Stemcell). K562 target cells (ECACC,) were loaded for 20 min with DELFIA BATDA reagent (Perkin Elmer) at 37°C, washed 5 times in PBS, 0.1% (v/v) BSA, 2.5 mM probenecid (ThermoFisher Scientific) and co-cultured with NK cells for 3 h at 37°C in the presence of 2.5 mM probenecid. Killing was assessed in supernatants by DELFIA EuTDA readout (Perkin Elmer). Percent specific killing was calculated from the fluorescence values of ((Sample -(Target cells only -medium) -(NK cells only -medium) -medium) × 100)/(100% lysis -medium).
Peptide-specific recall assay 2.5 × 10 5 /96-well of human PBMCs from donors prescreened for reactivity against CMV peptide NLVPMVATV. were stimulated with 3 μM MEDI9197 or DMSO and a titration of CMV peptide. After 5 days, cells were stained for flow cytometry analysis. A list of antibodies and details of flow cytometry can be found in Additional file 1 section.
Mice and rats
Female C57BL/6 J, BALB/cAnNCrl, C57BL/6 J-TyrC-2 J (C57BL/6 J Albino, Strain B6(Cg)-TyrC-2 J/J), CD-1® IGS mice (Crl:CD1(ICR)) (Charles River or Jackson Laboratories) at 6-10 weeks of age (~18-25 g) were used for in vivo studies. Male Sprague Dawley rats (Crl:CD (SD)), 200-400 g, were obtained from Charles River Laboratories.
In vivo studies
The melanoma cell line B16-OVA was obtained from Dr. Wynette Dietz, University of Minnesota. Cell suspensions were implanted subcutaneously: 5 × 10 5 B16-OVA cells, 5 × 10 3 B16-F10 AP3 CAG luc2 (AstraZeneca) cells in 1:1 Matrigel (Corning)/PBS, or B16-F10 AP3, 4 T1 and MC38 cells as previously described [25] .
Tumor For TIL analysis (gene expression or flow cytometry) tumors collected from 6 days after MEDI9197 treatment were enriched for responders. Responders are defined as tumors with drug-induced tumor growth inhibition (average tumor volume < 600 mm 3 ). 50% of MEDI9197 treated tumors were considered responders and groups were powered for this.
Quantitation of [
14 C]-MEDI9197 in rat tissues, whole blood, and plasma [ 14 C]-MEDI9197 was quantified in rat tissues, wholeblood, and plasma by Quotient Bioresearch Ltd., UK after SC injection. Whole-blood and plasma samples were collected via a tail vein or via cardiac puncture. Plasma samples were taken for direct Quantitative Radiochemical analysis (QRA). Whole-blood samples were taken for oxidation prior to QRA. Distribution of radioactivity in tissues was determined by quantitative whole-body autoradiography (QWBA). Tissue concentrations of radioactivity were determined using calibrated autoradiographic microscales (GE Healthcare). For calculation of the weight equivalent/g data, the nCi/g data was divided by the relevant specific activity (84.5 μCi/mg).
TNFα quantitation from rat serum
TNFα was measured in undiluted serum using Invitrogen's antibody bead kits, according the manufacturer's instructions. The LLQ for TNFα is 2 pg/mL.
MALDI mass spectrometry imaging
MALDI-MSI experiments were carried out in positive reflectron mode over a mass range of m/z 200 to 1000 using a MALDI rapifleX tissuetyper (Bruker Daltonics) equipped with a 10 kHz Smartbeam 3D™ Nd:YAG laser. Data collected on the rapifleX was at a spatial resolution of 50 μm, summing up 500 laser shots/raster position.
FlexImaging 5.0 (Bruker Daltonics) software was used for initial data analysis. Normalization, molecular image extraction and spectral clustering were defined in SCiLS Lab 2018b (Bruker Daltronics) software typically using mass selection window of ±0.05 Da. MEDI9197 and heme were detected at m/z 594.4 and 616.1, respectively.
MEDI9197 quantitation from tumors and serum
MEDI9197 quantitation was performed as previously described [27] .
Optical imaging of tumor burden
Mice implanted with B16-F10 CAG luc2 were administered Xenolight D-Luciferin K + salt bioluminescent substrate (IP, 100 μL of 33 mg/mL, PerkinElmer). 15 min after substrate injection, mice were imaged on an IVIS100 under isoflurane at an exposure time of 1 s using an open filter and field of view C. Image analysis was completed using living Image Software (PerkinElmer). Regions of interest were drawn around the tumors and total counts were generated within the region of interest.
Tumor histology
Excised tumors were immersed in 10% buffered formalin and sent to Marshfield Lab, Marshfield, WI for paraffin embedding, sectioning, H&E staining, and histopathology evaluation. Digital photomicrographs were taken from all sections, and the number of lymphoid aggregates per section were quantified by microscopy (Veterinary Pathologist, Marshfield Lab).
Tumor immune profiling by flow cytometry
Single cell suspensions from individual tumors were obtained using the murine tumor dissociation kit and a gentleMACS dissociator (Miltenyi Biotec). T and NK cells were stained with viability Zombie Aqua Dye (BioLegend) and fixed in 1% of paraformaldehyde at 4°C for 30 min prior to FACS analysis.
For in vitro activation of TILs and measurement of intracellular cytokine producing T cells, leukocytes were enriched using anti-mouse CD45 MicroBeads and collected on LC columns using a MACS separator (Miltenyi Biotec). TILs were collected and resuspended in 1 mL TexMACSmedium (Miltenyi Biotec) containing cell stimulation cocktail plus protein transport inhibitors (eBioscience/ ThermoFisher Scientific) for 16 h. Activated TILs were evaluated in staining buffer containing protein transport inhibitor cocktails (eBioscience/ThermoFisher Scientific) until the permeabilization/fixation step. A list of all FACS antibodies can be found in the Additional file 1 section.
Measurement of gene expression in mouse tumors
Tumors were stored in RNAlater® RNA stabilization solution at − 20°C (Life Technologies) then homogenized in RLT buffer using Miltenyi M tube with a gentleMACS dissociator. Total RNA was isolated using RNeasy Mini Kit according to the manufacturer's protocol. gDNA was removed using RNase-free DNase I (Qiagen).
cDNA was generated using RT2 First Strand Kit (Qiagen). qPCR assays were carried out either using RT2 Profiler PCR Array (Qiagen, Cat. no. 330171 CLAM24673) or PrimeTime qPCR assays (Integrated DNA Technologies). Probe lists can be found in the Additional file 1 section. All qPCR assays were performed with a LightCycler 96 (Roche) using cycling conditions provided by assay manufacturer.
Relative expression levels were quantified using ΔCt (GusB Ct -Target gene Ct).
Fold-Change = 2 -ΔCt(Treated) ÷ 2 -ΔCt(Control) = Relative quantitation of treated (MEDI9197) ÷ Relative quantitation of Untreated (Vehicle).
Measurement of tumor specific T cells by ELISpot
Tumors were excised at days 3, 7, and 11 post-dose (IT-20 μg MEDI9197 or IT-Vehicle). TILs were isolated from tumors as described above (Tumor immune profiling section). Lymphocytes from 1 to 3 animals were pooled and 20,000-100,000 lymphocytes per well were analyzed for IFNγ and Granzyme B expression using a dual color ELISpot assay (R&D Systems) following manufacturer's protocol. Lymphocytes were stimulated in duplicate for b [gp100 [25] [26] [27] [28] [29] [30] [31] [32] [33] : EGSRNQDWL and Influenza A nucleoprotein (366-374): ASNENMETM] peptide epitopes. SIINFEKL peptide was from InvivoGen all other peptides were from Genscript. All peptides were dissolved at 1 mg/mL in DMSO. ELISpot assay was performed following manufacturer's instructions. Spots were counted using a CTL ImmunoSpot S6 Micro using ImmunoSpot 7.0 ProDC suite (CTL Analyzers, LLC).
Human DC-T cell MLR primary cell assay
Human Mo-DCs were generated by differentiation of CD14 + monocytes (EasySep Human CD14+ positive selection kit (Stemcell)) in the presence of 100 ng/ml GM-CSF and 100 ng/mL IL-4 for 6 days in X-Vivo15 with 2% human AB serum. Mo-DCs were harvested, seeded, and stimulated with MEDI9197 for 18 h. Allogeneic human CD3 + T cells were isolated using the Human T cell enrichment kit (Stemcell), then added to the mo-DCs at a ratio of 10:1 and co-cultured for 3-5 days. IL-2 was measured by DELFIA ELISA (R&D) in day 3 supernatants and IFNγ (BD) in day 5 supernatants.
Results
MEDI9197 activates human innate and adaptive immune cells
MEDI9197 is a dual agonist for TLR7 and TLR8, as confirmed using HEK reporter cells transfected with human TLR7 or human TLR8 (Fig. 1a) . Like other imidazoquinolines, MEDI9197 also activates murine TLR7, induces IFNγ from mouse splenocytes and has no negative impact on cell viability (Additional file 1: Figure S1A -C). Imidazoquinolines do not agonise murine TLR8, which may account for lower potency in mouse splenocytes compared with human PBMCs.
Given the broad expression of TLR7 and 8 on myeloid subsets [28] we investigated the impact of MEDI9197 on human myeloid cells. MEDI9197 induced IFNα and IL12p40 release from pDC and mDC populations, respectively, which were enriched from human PBMCs (Fig. 1b) . The ability of MEDI9197 to activate human DC populations was further demonstrated by increased IL-12p70 production from Monocyte-derived DCs (Mo-DC) (Additional file 1: Figure S1D ). In human IFNγ-primed primary macrophages MEDI9197 induced IL-12p70 to significantly higher levels than a high dose of LPS (p = 0.0075; average of 33 vs. 14 ng/ml of IL-12 for MEDI9197 and LPS, respectively; Fig.  1c ). This shift in macrophage polarization is further evidenced by upregulation of CD40, CD80, IL12A and CD274 (PD-L1) gene expression (Additional file 1: Figure S1E ).
We next investigated the ability of MEDI9197 to stimulate innate and adaptive immune cells in human PBMC cultures. MEDI9197 induced the up-regulation of activation markers/co-stimulatory molecules from various human PBMC immune cell populations in vitro (Fig. 1d) (Fig. 1e) .
When compared to a C-class CpG (ODN2395) or a STING agonist (2′3'-c-di-AM (PS)2) only MEDI9197 induced high levels of the Th1 cytokines, IFNγ and IL12p70 from PBMC. The hook effect at high concentrations, which has been observed with other TLR7 agonists, is likely the result of differences in the rate of cytokine production [29] and is not due to cytotoxicity ( [28] , Additional file 1: Figure S1A ). MEDI9197 also induced significantly greater IFNα production compared to treatment with the STING agonist and was more potent than C-class CpG. (p = 0.0013; Fig. 1f) .
In addition to activating APCs, MEDI9197 enhanced the killing capacity of effector cells such as NK and T cells. Priming human PBMCs with MEDI9197 significantly increased target cell killing of K652 leukemia cells by isolated NK cells more than 2-fold at 10:1, 5:1 and even 2:1 NK:target cell ratio (p = 0.0001, p = 0.0013, p = 0.0185, respectively; Fig. 1g ). In the context of CMV-specific PBMCs, priming with MEDI9197 and CMV-peptide led to an expansion of peptide-specific CD8 + T cells ( Fig. 1h ) with increased effector function (Granzyme B, Fig. 1i ). Taken together these in vitro results show that MEDI9197 effectively stimulates the activation and function of innate and adaptive human immune cells.
MEDI9197 is retained at the site of injection and induces pharmacodynamic responses
The MEDI9197 lipid tail and formulation (sesame oil with 7.5% ethanol) have been designed to aid local retention of the TLR7/8 agonist at the site of injection to minimize systemic exposure and side effects, such as cytokine release syndrome (CRS). SC administration of radiolabelled MEDI9197 in rats revealed that MEDI9197 was retained at the site of injection for at least 28 days post dosing ( Fig. 2a and b) . Radiolabelled MEDI9197 was detectable in plasma and whole blood for at least 14 days (Fig. 2c) . However, peak levels of MEDI9197 measured by LC-MS/MS in the serum from rats dosed SC or intramuscularly (IM) remained below 3 ng/mL (Additional file 1: Figure S2A , B). This is 20 times lower than the minimum effective concentration (MEC) of 59 ng/mL for MEDI9197 to induce cytokines from human PBMCs in vitro (data not shown). Low systemic exposure and subsequent pharmacodynamic (PD) effects of MEDI9197 were examined further in a separate rat study. MEDI9197 induced very low levels of systemic serum TNFα levels (peaking at 16 pg/mL 18 h post-dose) compared with Resiquimod (1212 pg/mL 2 h post-dose) after SC dosing (Fig. 2d) .
MEDI9197 retention at the site of injection was qualitatively observed in the B16-F10 AP3 mouse melanoma model following administration of 20 μg MEDI9197 injected IT, by 
mass spectrometry (MS) imaging. MEDI9197 location in a section of excised tumor, indicated in green, was still detectable in concentrated regions of the tumor for at least 8 days post injection (Fig. 2e) . The Heme signal is a measure of blood in the tissue slice, related to tissue damage, such as haemorrhage or necrosis. The signal for MEDI9197 does not colocalise with the MS signature for Heme (shown in red), therefore it is unlikely to be localized to a non-viable region of tissue. To determine the time-course of drug retention in B16-F10 tumors, MEDI9197 was quantified in homogenized tumors using HPLC-UV 6 h to 14 days after injection revealing that approximately 50% (indicated by dotted line) of the initial dose was retained in the tumor for approximately 9 days post injection (Fig. 2f ). These data demonstrate that MEDI9197 is retained at the site of administration for up to 4 weeks after injection, with low systemic exposure.
To further evaluate the immunological effects of MEDI9197 retention at the injection site, naïve mice were SC injected with MEDI9197 or Resiquimod. Expression of TNFα, IL-12p40 and IFNγ mRNA was measured in the axilliary and brachial lymph nodes (dLN) proximal to the injection site (Additional file 1: Figure  S3 ). The local dLN response was delayed with MEDI9197 (Tmax 6 h) compared to Resiquimod (Tmax 1 h). In the spleen, Resiquimod also induced rapid (Tmax 1 h) upregulation of these cytokine transcripts. MEDI9197, however, induced minimal changes in splenic TNFα, IL-12p40 and IFNγ expression after SC administration (Additional file 1: Figure S3 ). Thus, local retention of MEDI9197 minimizes distal inflammatory cytokine induction. SC injection of either MEDI9197 or Resiquimod induced expression of type I IFN response related genes (MX1, OAS2, Tnfs10) both in the dLN as well as peripherally in the spleen. However, the Tmax of gene expression for MEDI9197 dosed mice was 6 h, compared with 1 h for Resiquimod dosed mice (Additional file 1: Figure S3) . Overall, these results show that retention of MEDI9197 at the injection site leads to a prolonged localized immune response with minimal systemic exposure or inflammatory cytokine expression.
MEDI9197 induces a range of immunological changes within the tumor microenvironment (TME) resulting in anti-tumor efficacy Next, we investigated the effects of MEDI9197 on the TME and growth. MEDI9197, but not Resiquimod, administered IT, on days 8 and 15 post tumor cell implantation, significantly inhibited tumor growth and enhanced long-term survival by 12 days (p ≤ 0.0005) in mice bearing established B16-OVA melanoma tumors ( Fig. 3a and Additional file 1: Figure S4a ). When MEDI9197 was administered to mice SC, on the contralateral flank of the B16-OVA tumor, it was ineffective in mediating tumor control. Therefore, administration and retention of MEDI9197 at the tumor site is required for anti-tumor activity. Repeat dosing or doses higher than 20 μg administered IT did not further enhance anti-tumor activity (Additional file 1: Figure S4B-D) . Furthermore, we show that IT administration of MEDI9197 can inhibit tumor growth in tumors previously described [25] to have: high (MC38); low (B16-F10 CAG luc2); and suppressive (4 T1) immune cell infiltrates (Fig. 3b) . This highlights the potential of IT MEDI9197 to alter a wide range of TMEs to promote anti-tumor immunity. Additionally, imaging of luciferase expression in the B16-F10 CAG luc2 cells as an indicator of tumor burden demonstrates that MEDI9197 is effective at doses of 0.4 or 20 μg (Fig. 3c) .
Since localization of MEDI9197 in the TME is required for anti-tumor activity, we sought to test the hypothesis that MEDI9197 induces local conversion of the tumor immune infiltrate to promote anti-tumor immunity. Histological examination of B16-OVA tumors, 7 days after MEDI9197 treatment, revealed formation of lymphoid aggregates (ectopic lymph nodelike structure) (Fig. 4a and b) indicative of localised were evaluated in H&E stained tissue sections. Eight days after B16-OVA tumors were implanted SC into C57BL/6 J albino mice (3/group), a single dose of 20 μg MEDI9197 or Vehicle was administered IT. Some mice were untreated (Naïve, n = 3). After 1-and 7-days post-dose, FFPE tumors were sectioned, H&E stained, and scored for lymphoid aggregates. Each tumor photomicrograph is from one mouse and is representative of each treatment group. Data is representative of 3 independent experiments in the B16-OVA model. b Number of lymphoid aggregates per section for each mouse from each group is shown 1-and 7-days post-dose. Statistical analysis was performed by two-way ANOVA with Tukey's post hoc test. ***p = 0.001, ****p < 0.001 immune responses. In comparison, Vehicle treated or naïve tumors had minimal or no lymphoid aggregates (Fig. 4b) .
Gene expression analysis of MEDI9197 treated tumors compared with Vehicle treated tumors showed a strong upregulation of immune related genes in a subset of tumors treated with MEDI9197 (Additional file 1: Figure  S5 ). At 7 and 11 days post-dose, a cohort of mice could be separated based on response to MEDI9197 treatment by tumor size compared with the Vehicle group. Those mice showing drug-induced tumor growth inhibition (tumour volume < 600 mm 3 , Responders) also correlated with the subset of tumors with a strong upregulation of immune related genes in contrast to those with no tumor growth inhibition which were similar to Vehicle control group, Non-responders. To better understand the mechanism of action for MEDI9197 anti-tumor activity, tumors that are responding to MEDI9197 treatment, based on tumor size compared with Vehicle, were used for pharmacodynamic analyses, where possible. We went on to characterize the changes in the immune phenotype of the TME. MEDI9197 treatment quickly induces a type I IFN response demonstrated by an increase in IFN-inducible genes (e.g. Mx1, Isg15, Ifit1 and Ifit3, Fig. 5a ), which were increased at 3 days and peaked at 7 days post-dose. Expression of CD8 + T cell response genes (e.g. FasL, GzmB, and IFNg, Fig. 5b ) peaked at 7 days post-dose and remained elevated at 11 days post-dose (e.g. IFNγ was approximately 32-fold and 15-fold higher than Vehicle control, respectively). Furthermore, the proportion of TILs made up by CD8 + T cells significantly increased 7 days and 11 days after MEDI9197 treatment (p = 0.0132 and p = 0.0589, respectively, compared with vehicle treatment), whereas the relative abundance of CD4 + T cells was decreased 11 days post-dose (Fig. 5c , Additional file 1: Figure  S6B ). Additionally, MEDI9197 enhanced activation of both CD4 + and CD8 + T cells at all timepoints tested (increased %CD69 + cells observed 1 day, 7 day and 11 days post-dose, Fig. 5d , Additional file 1: Figure  S6B ). NK cell activation in the tumor followed the same kinetics as T cell activation, but unlike CD8 + T cells, MEDI9197 did not increase the proportion of NK cells in the tumor (Additional file 1: Figure  S6A and B). Overall, these results indicate that a single IT dose of MEDI9197 induces T cell and NK cell activation beginning 1 day after treatment and lasting at least 11 days post-dose and drives a significant increase in the relative abundance of CD8 + T cells at later timepoints.
We have observed that MEDI9197 can enhance human NK cell killing of target cells (Fig. 1) and can induce NK cell activation in vivo (Additional file 1: Figure  S6A ), whereas Singh et al. [23] have previously demonstrated that MEDI9197 anti-tumor activity is dependent on CD8 + T cells, but not NK cells, using depletion studies in the B16-OVA model, suggesting NK cells may be involved but are not required for the anti-tumor activity observed in the B16-OVA model, so we focused on further evaluation of the functional status of TILs. MEDI9197 induced an increase in total effector T cells ) in the tumor 6-8 days after dosing (Fig. 5e, Additional file 1: Fig. 6e ). In keeping with the induction of IFNγ gene expression in the TME detected by qPCR 7 days post-dose (Fig. 5b) , MEDI9197 dosing induced a significant increase in the proportion of CD8 + T cells expressing IFNγ compared to the Vehicle group (p < 0.0001; 79.8% versus 17.6%) following ex vivo stimulation with PMA/ionomycin (Fig. 5f , Additional file 1: Figure S6D ). The lower panels in Fig. 5f indicate that MEDI9197 induces significantly more double-positive (IFNγ/TNFα) CD8 + T cells compared to the Vehicle group (p = 0.0041; approximately 60% versus 10%). In contrast, most (about 70%) of the Vehicle-treated CD8 + T cells were single-positive (TNFα). There was no significant difference in the percentage of triple-positive (IFNγ/TNFα/IL-2) CD8 + T cells with MEDI9197 compared with Vehicle treatment. Eleven days post-dose, T cells from the tumor were responsive to multiple tumor associated antigens as demonstrated by IFNγ and granzyme B release after ex vivo stimulation with OVA or melanoma associated peptides (p53, TRP-2, gp100 and MAGE-A5) (Fig. 5g) . These data indicate MEDI9197 induced upregulation of type I IFN response, IFNγ, and CD8 + T cell activation, all indicators of conversion to a hot TME favourable for anti-tumor immunity. 
MEDI9197 enhances activity of IO therapies
The robust localized activation of immune cells and further recruitment of CD8 + TILs following MEDI9197 IT dosing indicates that this approach may compliment other IO therapies. We found that MEDI9197 induces an increase in gene expression for immune inhibitory (e.g. PD-1, PD-L1) and T cell co-stimulatory molecules (e.g. GITR and OX40) in the injected tumor ( Fig. 6a and  b) . Based on the ability of MEDI9197 to induce CD8 + T cell activation and IFNγ production, as well as the increase in PD-1 and PD-L1 gene expression observed in the tumor after MEDI9197 treatment (Fig. 6a) , it is not surprising that MEDI9197 also induced a significant increase in surface PD-1 expression on TILs, especially CD8 + T cells (p < 0.05 on CD45 + cells and p = 0.0059 on CD8 + effector T cells; Fig. 6c and d, Additional file 1: Figure S6C ). MEDI9197 also induced a significant increase in PD-L1 on TILs including CD8 + T cells (p < 0.01 on CD45 + cells and p = 0.0012 on CD8 + effector T cells). Although a greater proportion of CD8 + T cells in the MEDI9197 group expressed cell surface PD-1 compared to PD-L1 (50% versus 10%), there were more CD8 + T cells in MEDI9197-treated tumors that expressed both cell surface PD-1 and PD-L1 (about 10% compared to 1% in the Vehicle group).
Given the increase in co-stimulatory or inhibitory molecules following IT dosing with MEDI9197 we explored whether combining MEDI9197 with T cell targeted therapies would result in enhanced antitumor efficacy. Similar to previous reports in the B16-F10 model [23] , we found that MEDI9197 increases median survival observed with anti-PD-L1 mAb in the B16-OVA model from 29 to 34.5 days (Fig. 6e) and resulted in 2 out of 10 tumors regressing without regrowth for 59 days post tumor cell implantation, so we extended these findings to a human co-culture in vitro assay. Using a primary human DC-T cell mixed lymphocyte reaction (MLR) assay, we show that combining a PD-L1 blocking mAb (MEDI4736, durvalumab) with MEDI9197 increased IL-2 and IFNγ cytokine production versus MEDI9197 alone (Fig. 6f) .
To examine the combination potential of MEDI9197 with T cell co-stimulatory molecules, an OX40 agonist mAb or GITRL fusion protein (FP) was combined with a suboptimal dose of MEDI9197 in the B16-OVA model. While neither the OX40 agonist mAb, GITRL FP, nor MEDI9197 was efficacious as a monotherapy, significant tumor growth inhibition was observed when combining MEDI9197 administered IT with systemic administration of an anti-OX40 agonist (p = 0.005; compared with anti-OX40 alone) or a GITRL FP agonist (p ≤ 0.0001; compared with GITRL FP alone) (Fig. 7) .
Discussion
We report here that MEDI9197 is a TLR7/8 agonist driving robust activation of human adaptive and innate immune cells including both mDC and pDC. Like TLR7/8 agonists, TLR9 agonists and STING agonists delivered IT also promote anti-tumor immunity in mouse models [19, 30] , and are currently being investigated in clinical trials (NCT02675439, NCT03172936, NCT02254772). However, we report here that these agonists have different effects on human immune cells. In particular, MEDI9197 activates human immune cells to secrete IFNα, IL-12 and IFNγ, whereas TLR9 and STING agonists only induced IFNα from human PBMC. Together this broader cytokine profile may be more effective at enhancing CD8 + T cell responses whilst inhibiting MDSC and Treg cells. Note that TLR9 is not expressed in human monocytes and myeloid dendritic cells, unlike TLR7 and TLR8 [31] , which in part may explain the reduced ability of TLR9 ligands to enhance CD8 T cell responses in humans [32] .
Despite the potent anti-tumor activity of systemic TLR agonists in pre-clinical models, clinical development of these agents has been hampered by the induction of CRS, and a lack of efficacy at tolerated doses [4, 10, 11, [33] [34] [35] [36] [37] [38] . We report here that the unique structure and formulation of MEDI9197 enables it to be retained within the tumor after IT delivery, minimising systemic drug exposure and cytokine release, and driving sustained local TLR7/8 activation in the TME. It is likely that the limited changes in circulating TNFα cytokine levels observed following local MEDI9197 treatment were due to "spill over" of cytokines released from local immune cells at the injection site, since no systemic TNFα gene expression was detected in the spleen. Furthermore, retention and prolonged immune activation in the tumor by MEDI9197 appear critical for its anti-tumor activity, since IT delivery of Resiquimod, which rapidly disseminates and leads to systemic immune activation, failed to drive anti-tumor activity. Similarly, SC delivery of MEDI9197 at a site distal to the tumor was ineffective. The variability in dose retention (such as local dissemination at the treatment site) and the local immune milieu at the injection site may account for the variability observed in response to MEDI9197. Positive responses to ICB therapy in patients has been shown to correlate with CD8 + T cell infiltration [3] . Tumors with low T cell infiltrate represent a significant unmet need. We report that activation of TLR7/8 in the tumor results in sustained transformation of the TME. In particular, MEDI9197 induced increased immune infiltration and the formation of ectopic lymph node structures in B16-OVA tumors. Type I IFN response genes were upregulated, CD8 + T cell infiltration was enhanced, and these cells were activated, expressing IFNγ. These data showing increased presence of CD8 + T cells and IFNγ suggest MEDI9197 IT delivery induces TME conversion to a hot immune phenotype. A similar inflammatory influx also correlated with tumor regression in response to topical Aldara (5% Imiquimod cream) in patients [39] . We have also shown increased NK cell killing of target cells and increased expression of CD69 on NK cells from mouse TILs, suggesting a role for NK cells in the anti-tumor activity of MEDI9197, which warrants further investigation.
The ability of MEDI9197 treatment to convert tumors from 'cold' to 'hot' make it an attractive co-therapy for ICB. PD-1, PD-L1, and CTLA4 and co-stimulatory molecules CD40, GITR, and OX40 are potential targets since MEDI9197 upregulates their expression in the TME. Our results confirm previous work demonstrating enhanced anti-tumor immunity in preclinical mouse models to the combination of MEDI9197 with PD-L1 blocking antibodies [23] . Furthermore, we go on to show combining MEDI9197 with PD-L1 blockade enhanced IFNγ production in a human DC/T cell MLR assay strengthening the rationale for combining MEDI9197 with ICB therapies targeting PD-1/PD-L1 interactions. The combination of MEDI9197 with GITRL FP or OX40 mAb also enhanced anti-tumor activity in the B16-OVA model. Studies in additional syngeneic models might provide insight into how different TMEs would impact on the activity of these combinations. These data are in agreement with the recent findings of Sagiv-Barfi et al [40] that in situ vaccination of an OX40 agonist with either TLR9 agonist SD-101 or Resiquimod resulted in an enhanced systemic anti-tumor immune response. Similar to our observations with MEDI9197, they also observe an increase in OX40 expression after intratumoral injection of SD-101. Beyond T cell-targeted therapies, others have also reported that MEDI9197 combination with CpG ODN enhanced antitumor immunity in mouse models. [24] . In addition, combinations of MEDI9197 with standard of care treatments for cancer, such as chemotherapy and radiotherapy, that drive release of tumor antigens are attractive given the observed vaccine adjuvant activity of MEDI9197 [22, [41] [42] [43] . Indeed, TLR7 agonists have previously been reported to enhance efficacy in combination with radiotherapy and chemotherapy in syngeneic mouse tumor models [44, 45] .
Conclusions
MEDI9197 is a TLR7/8 agonist that promotes robust and broad activation of human immune cells. MEDI9197 is uniquely retained at or near the site of injection to cause prolonged immune activation within the TME and in the local draining lymph nodes. IT injection of MEDI9197 results in tumor regression and enhanced survival in multiple mouse tumor models. IT therapy with MEDI9197 dramatically alters the TME by increasing CD8 + T cell infiltration and activation, increasing anti-tumor cytokines, and upregulating immune checkpoint expression. Combining MEDI9197 with other immune-modulatory agents can enhance anti-tumor activity, suggesting several routes to explore the utility of MEDI9197 in the clinic. MEDI9197 has been evaluated in Phase I clinical trials. 
